Cipher Pharmaceuticals Inc - Asset Resilience Ratio
Cipher Pharmaceuticals Inc (CPH) has an Asset Resilience Ratio of 4.80% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Cipher Pharmaceuticals Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Cipher Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See CPH defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Cipher Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cipher Pharmaceuticals Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$7.49 Million | 4.8% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$7.49 Million | 4.80% |
Asset Resilience Insights
- Limited Liquidity: Cipher Pharmaceuticals Inc maintains only 4.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cipher Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Cipher Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Krka d. d
WAR:KRK |
Drug Manufacturers - Specialty & Generic | 11.18% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Guangdong Taienkang Pharmaceutical Co. Ltd
SHE:301263 |
Drug Manufacturers - Specialty & Generic | 6.08% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Cipher Pharmaceuticals Inc (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Cipher Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.80% | CA$7.49 Million ≈ $5.42 Million |
CA$156.22 Million ≈ $113.01 Million |
-6.18pp |
| 2024-12-31 | 10.98% | CA$17.84 Million ≈ $12.90 Million |
CA$162.51 Million ≈ $117.56 Million |
-35.32pp |
| 2023-12-31 | 46.29% | CA$39.83 Million ≈ $28.81 Million |
CA$86.03 Million ≈ $62.23 Million |
+7.21pp |
| 2022-12-31 | 39.09% | CA$28.84 Million ≈ $20.86 Million |
CA$73.78 Million ≈ $53.37 Million |
-- |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more